{Reference Type}: Journal Article
{Title}: Anti-IL-23 treatment with tildrakizumab can be effective in omalizumab-refractory chronic spontaneous urticaria: A case series.
{Author}: Bonnekoh H;Kiefer L;Buttgereit T;Kolkhir P;Lütke-Eversloh M;Scheffel J;Maurer M;Metz M;
{Journal}: J Allergy Clin Immunol Pract
{Volume}: 11
{Issue}: 8
{Year}: 2023 08 25
暂无{DOI}: 10.1016/j.jaip.2023.05.019